Researchers from a Japanese university have successfully utilized CRISPR-Cas9 technology to remove the extra chromosome responsible for Down syndrome from human cells. This breakthrough involves a form of gene therapy that targets the third copy of chromosome 21, also known as trisomy 21, which typically leads to symptoms such as muscle weakness, organ defects, and cognitive challenges.The CRISPR-Cas9 system functions like molecular scissors, using a custom RNA fragment to guide an enzyme to specific locations in the genome to perform precise cuts. In this specific experiment, scientists identified recognition sequences unique to the redundant chromosome to facilitate its removal. The method was tested on both pluripotent stem cells and mature skin fibroblasts to determine if it could work in both dividing and non-dividing cells.While the experiment is a significant milestone, there are substantial obstacles to overcome before it can become a viable medical treatment:

• Low Efficiency: The current success rate for chromosome removal reached only 30.6% in laboratory cell cultures. Experts anticipate that efficiency would be even lower in vivo (inside a living organism) due to delivery challenges.
• Immune Response: There is a risk that the human body could trigger an immune response against the Cas9 proteins used in the therapy.
• Mosaicism: A major concern is the development of mosaicism, where different tissues in the body end up with different chromosomal configurations. This "puzzle-like" mismatch of cells could result in negative health consequences.
• Off-target Effects: There is a risk that the system might unintentionally modify healthy copies of chromosome 21 or other similar sequences elsewhere in the genome.
• Timing of Intervention: For the therapy to be most effective, it would likely need to be administered during the embryonic or fetal stages of development. Intervening after birth might only allow for the modification of specific tissues, which is of questionable efficacy.

Historical precedents emphasize the need for caution. Early gene therapy trials in the 1980s failed to replicate animal successes in human patients. Additionally, a notable case in 1999 resulted in the death of a young patient due to a cytokine storm—a massive systemic inflammatory response—triggered by the viral vector used to deliver a gene therapy. These events led to much stricter regulations and oversight for genetic research.Despite these complexities, this research marks a "new frontier" because removing an entire chromosome is far more complex than repairing a single gene. While a clinical therapy remains far off, the study opens new therapeutic possibilities for Down syndrome and potentially other chromosomal disorders.

Become a supporter of this podcast: https://www.spreaker.com/podcast/whole-life-studio--6886552/support.